Smart regulation: Will the government's strategy work?

CMAJ. Canadian Medical Association Journal

Volumn 173, Issue 12, 2005, Pages 1469-1470

  Graham, Janice ^a,b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COST BENEFIT ANALYSIS; ECONOMIC ASPECT; ENVIRONMENTAL MONITORING; FINANCIAL MANAGEMENT; GOVERNMENT; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH HAZARD; NOTE; PUBLIC HEALTH; SAFETY; SCIENCE; SOCIAL ASPECT; SOCIOECONOMICS;

EID: 28944440034     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.050424     Document Type: Note

References (13)

1. Smart regulation: report on actions and plans. Ottawa: Government of Canada; Mar 2005. Available: www.regulation.gc.ca/docs/reporti/rap_e.pdf (accessed 2005 May 27).
2. Government of Canada. External Advisory Committee on Smart Regulation. Committee members. Available: www.pco-bcp.gc.ca/smartreg-regint/en/01/mb-01.html (accessed 2005 Nov 7).
3. Office of the Prime Minister. Prime Minister receives report on smart regulation from the External Advisory Committee on Smart Regulation. 2004. Available: www.pm.gc.ca/eng/news.asp?id=269 (accessed 2005 May 27).
4. Canadian Environmental Law Association. Letter to External Advisory Committee on Smart Regulation. 2004 May 17. Available: http://cela.ca/uploads/ f8e04c51a8 e04041f6f7faa046b03a7c/EACSR_mayltr.pdf (accessed 2005 Nov 7).
5. Standing Committee on Health. Evidence contents of meeting 31: Bill C-28, an Act to Amend the Food and Drug Act (interim marketing authorizations). Ottawa: House of Commons (2005 Apr 11) at 16:40 [McBane M]. (Chair: B Brown). Available: www.parl.gc.ca/committee/CommitteePublication.aspx?SourceId=111843 (accessed 2005 Nov 8).
6. Heilbroner R. 21st century capitalism. New York: WW Norton; 1993. p. 91.
7. Okie S. What ails the FDA? N Engl J Med 2005;352:1063-6.
8. Wood AJ. The safety of new medicines: the importance of asking the right questions. JAMA 1999;281:1753-4.
9. Lasser KE, Allen PD, Woolhandler SJ, et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287:2015-20.
10. Lexchin J. Drug withdrawals from the Canadian market for safety reasons, 1963-2004. CMAJ 2005;172(6):705-7.
11. Wingspread statement. Ames (Iowa): Science and Environmental Health Network; 1998. Available: www.sehn.org/precaution.html (accessed 2005 Nov 7).
12. "Smart Regulation" is a smart idea for Canada [press release]. Ottawa: Business Coalition on Cost Recovery; 2004 Sept 23. Available: www.ccpa.ca/files/Public_Affairs /BCCR_-_Smart_Regulation_News_Release_Sept_2004.doc (accessed 2005 Nov 7).
13. Mintzes B, Barer ML, Kravitz RL, et al. How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. CMAJ 2003;169(5):405-12.